Scienture (NASDAQ:SCNX) Trading Down 6.6% – Time to Sell?

Posted by ABMN Staff on Jul 22nd, 2026

Scienture Holdings, Inc. (NASDAQ:SCNX – Get Free Report) shares were down 6.6% during mid-day trading on Tuesday . The stock traded as low as $0.3750 and last traded at $0.3886. Approximately 316,716 shares were traded during trading, a decline of 92% from the average session volume of 3,902,358 shares. The stock had previously closed at $0.4160.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Scienture presently has an average rating of “Hold” and a consensus target price of $1.50.

Get Our Latest Stock Report on Scienture

Scienture Stock Performance

The stock has a market capitalization of $15.79 million, a P/E ratio of -0.15 and a beta of 3.28. The stock has a 50 day moving average of $0.38 and a 200 day moving average of $0.41.

Scienture (NASDAQ:SCNX – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.15. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.40 million.

Institutional Trading of Scienture

An institutional investor recently bought a new stake in Scienture stock. Virtu Financial LLC acquired a new position in Scienture Holdings, Inc. (NASDAQ:SCNX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned 0.22% of Scienture as of its most recent SEC filing. 5.68% of the stock is currently owned by institutional investors and hedge funds.

About Scienture

(Get Free Report)

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.